Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence

PENGHUI SONG1, JING HU2, XIJIN LIU3 and XUEJUN DENG1

1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022; 2Department of Neurology, Huaihe Hospital, Henan University, Kaifeng, Henan 475000; 3Department of Neurology, Ordos Center Hospital, Ordos, The Nei Mongol Autonomous Region 017000, P.R. China

Received October 10, 2018; Accepted March 27, 2019

DOI: 10.3892/mmr.2019.10202

Abstract. Previous studies have indicated that the adenosine triphosphate-sensitive homomeric P2X7 receptor (P2X7R) plays an important role and exhibits therapeutic potential in a number of brain disorders, including temporal lobe epilepsy (TLE). The aim of the present study was to assess the expression of P2X7R, glutamate (GLU) and glial fibrillary acidic protein (GFAP) in the temporal neocortex and hippocampus of rats with lithium-pilocarpine-induced epilepsy as well as in patients with intractable TLE. The results demonstrated that the levels of P2X7R, GLU and GFAP were significantly upregulated in rats with spontaneous recurrent seizures, whereas they were reduced in rats that were treated with brilliant blue G (BBG), a P2X7 antagonist. To the best of our knowledge, the present study is also the first to demonstrate that P2X7r expression was elevated in patients with intractable TLE. These findings suggest that P2X7R plays a key role in the development of TLE and that BBG treatment may be a promising therapeutic strategy for TLE.

Introduction

Epilepsy is a common cerebral disease characterized by interictal epileptiform discharge, which affects nearly 9 million people in China, among whom ~25% (>2.2 million) are considered to have refractory epilepsy (1). Previous studies have demonstrated that the development of temporal lobe epilepsy (TLE) is associated with both abnormal structure and dysfunction of the brain, such as hippocampal neuron regeneration, mossy fiber sprouting, synaptic reconstruction and astrocyte proliferation (2-4). Developing an effective treatment for TLE remains an important research focus.

The concept of the ‘purine receptor’ has been used to describe cell membrane adenosine receptors and adenosine triphosphate (ATP) receptors (5). ATP is an energy currency unit that is essential for cell function and organization of biological signaling molecules (6). According to the International Association of Pharmacology classification of receptors and drug names, receptors that are sensitive to extracellular adenosine are referred to as P1 receptors, whereas those that are sensitive to extracellular nucleotides are referred to as P2 receptors. P2 purinergic receptors are subclassified into two types, i.e., P2X and P2Y. P2X is an ATP ligand-gated ion channel. When extracellular ATP binds to the P2X receptor, the P2X channel opens, allowing cations to pass through the cell membrane (7-10).

The P2X7 receptor (P2X7R) is abundantly distributed in the cerebrum (11), including the solitary nucleus, hippocampus, habenular nucleus and substantia nigra pars compacta (12). In addition, it performs numerous physiological functions, such as regulation of neurotransmitter release, stimulation of proinflammatory cytokines and induction of cell damage and apoptosis (13,14). However, whether P2X7R is involved in the development of TLE remains unknown. Therefore, the aim of the present study was to assess the expression of P2X7R in rat and human brain tissue samples from epileptic and non-epileptic subjects using immunohistochemical techniques, in order to elucidate the role of P2X7R in epilepsy, particularly its possible implications in the pathogenesis of TLE.

Materials and methods

Animals. A total of 90 male Sprague-Dawley rats (age, 2 months; weight, 200-250 g) were raised under controlled conditions (temperature 24-25°C, humidity 50-60% and a 12-h light/dark cycle). The animals had ad libitum access to food and water. All procedures were implemented according to the guidelines of the Animal Care Committee of Huazhong University of Science and Technology and the study protocol was approved by the Ethics Committee of Huazhong University of Science and Technology.

Drugs. The following drugs were used in the present study: Pilocarpine hydrochloride (Sigma-Aldrich; Merck KGaA,
Animal model of TLE. First, the rats were administered an intraperitoneal (IP) injection of lithium chloride (127 mg/kg). After 18 h, atropine sulfate (1 mg/kg, IP) was injected, followed by pilocarpine hydrochloride (15 mg/kg, IP) after a further 30 min. The seizure severity was graded according to Racine's standard classification as follows: Stage 1, movement of the mouth and face; stage 2, nodding of the head; stage 3, clonus of the unilateral forelimb; stage 4, clonus and rearing of the bilateral forelimbs; and stage 5, stage 4 seizure with episodes of falling. Pilocarpine hydrochloride injection (15 mg/kg, IP) was repeated every 30 min if there was no seizure, or if seizure activity did not reach stage 4 on the Racine scale. The maximum dose of pilocarpine hydrochloride was 60 mg/kg. When status epilepticus persisted for 1 h, it was terminated by an injection of diazepam (10 mg/kg, IP). The present experiment only used rats graded at stage 4 or 5.

Behavioral observation. A total of 2 weeks after the onset of status epilepticus, all rats underwent uninterrupted video monitoring throughout the daytime to observe whether any spontaneous repeated seizures occurred over 7 weeks. Behavioral parameters, including latency period, frequency of spontaneous recurrent seizure, duration of chronic epilepsy and mortality were analyzed during the entire study period.

Electroencephalogram monitoring. Rats were anesthetized with 10% chloral hydrate (0.3 ml/100 g, IP) to undergo an electroencephalography (EEG). The rats were fixed and two electrodes were inserted underneath the scalp on both sides in the temporal region (0.65 cm in front of the connection of the external ear gate and 0.4 cm beside the center line). The reference electrode was inserted underneath the scalp at the frontal pole midpoint (1.2 cm in front of the external ear gate). EEG waveforms filtered <0.53 Hz and >30 Hz were subjected to analog-to-digital conversion by a dynamic electroencephalography device (Beijing Symtop Instrument Co., Ltd., Beijing, China). When the rats entered the spontaneous recurrent seizure period, they underwent EEG monitoring for 4 h once per week to record EEG waveforms and spike-wave discharges. Some rats with spontaneous recurrent seizures were injected with brilliant blue G (BBG) or saline for 2 weeks and EEG waveforms were recorded 30 min before and 60 min after the injection.

Animal grouping and treatment. This study used a total of 90 male Sprague-Dawley rats, among which 6 were given an IP injection of saline solution to serve as the control group, whereas the remaining 84 were used to establish models of epilepsy. A total of ~21 rats had no epileptic seizures, among which 5 were randomly selected to comprise the acute seizure group. A total of 13 rats died after the onset of status epilepticus, 8 rats died during the latency period, 9 rats were in the spontaneous recurrent seizures group and 28 rats were in a chronic phase of spontaneous recurrent seizures. These 28 rats were randomly divided into two groups: the BBG group (21 rats) and the saline group (7 rats). The BBG group was further randomly divided into 3 subgroups (7 rats each) that were separately administered IP injections of BBG at different doses (50, 100 or 200 mg/kg) for 2 weeks.

Patients with TLE. From June 2017 to June 2018, a total of 25 patients with TLE (15 men and 10 women; age range, 18-55 years) from the Wuhan Union Hospital in China were included in the present study. All the patients had characteristic EEGs and representative clinical features (mean number of seizures, 5.5/month), and were on the highest dose of ≥3 antiepileptic drugs (AEDs), such as valproic acid, oxcarbazepine, ethosuximide, lamotrigine, and clonazepam. All patients underwent presurgical assessment including medical history review, detailed neurological examination and ictal or normal EEG studies; they also underwent magnetic resonance imaging (MRI), video EEG, and sphenoidal electrode EEG prior surgery. All brain MRI scans demonstrated no progressive disease in the central nervous system. All patients underwent surgery to remove the epileptogenic zone in the temporal neocortex. For comparison purposes, from June 2017 to June 2018, 6 patients with head trauma (3 men and 3 women; age range, 12-60 years) whose neocortices were histologically normal and who had no history of epilepsy or use of AEDs were examined. All procedures adhered to the conduct of research involving human subjects established by the National Institutes of Health of China and the Committee on Human Research of Huazhong University of Science and Technology. All subjects provided written informed consent to participate in this study.

Tissue processing. The rats were anesthetized with 10% chloral hydrate (0.3 ml/100 g, IP) and then quickly perfused with 4% paraformaldehyde in PBS. After embedding in paraffin, the brain tissue was sliced into 4-μm sections. Similarly, 4-μm sections were prepared from the 4% paraformaldehyde-fixed and paraffin-embedded human brain tissue samples.

Immunohistochemical staining. First, rat hippocampal sections were incubated with 5% bovine serum albumin (Cell Signaling Technology, Inc., Danvers, MA, USA) in PBS for 30 min at room temperature. Subsequently, the sections were incubated with anti-P2X7 immunoglobulin G (cat. no. ab48871; 1:100), anti-GLU IgG (cat. no. G9282; 1:100), or anti-GFAP IgG (cat. no. ab33922; 1:100) overnight at 4°C. The sections were washed in PBS for three times for 10 min each time and then incubated with an Alexa® 594-conjugated secondary antibody (cat. no. ab150160; 1:100; Abcam) for 40 min at 4°C. Then, the sections were visualized with 3,3′-diaminobenzidine for 5 min at room temperature in the dark, rinsed in distilled water and dehydrated in a graded ethanol series. Negative control sections were incubated with PBS instead of the primary antibody.
antibody. Images were captured via fluorescence microscopy at the same magnification (x200) and grayscale was measured using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

Western blotting. The tissues were harvested, and total cell lysates were prepared using a protein extraction kit (Wuhan Servicebio Technology Co., Ltd., Wuhan, China), following the manufacturer's protocol. Protein concentrations were quantified using a bicinchoninic acid kit (Beyotime Institute of Biotechnology, Haimen, China). Subsequently, 50 µg samples were boiled in gel-loading buffer and separated by 10% SDS-PAGE. The proteins were transferred to polyvinylidene difluoride membranes (Bio‑Rad Laboratories, Inc., Hercules, CA, USA) and blocked at 37˚C with 5% skimmed milk powder in Tris-buffered saline for 1 h. Then, the blots were incubated for 6 h at 37˚C with anti-P2RX7 (cat. no. ab48871; 1:1,000; abcam) and β-actin (cat. no. ab8226; 1:2,000; abcam) antibodies independently. The membranes were then incubated for 1 h at 37˚C with goat anti-rat horseradish peroxidase-conjugated secondary antibody (cat. no. ab150160; 1:100; abcam) antibodies independently. The membranes were then incubated for 1 h at 37˚C with goat anti-rat horseradish peroxidase-conjugated secondary antibody (cat. no. ab150160; 1:100; abcam). Chemiluminescent signals were detected using the Enhanced Chemiluminescent Plus kit (KPL, Inc., Gaithersburg, MD, USA) and the signal intensity was measured by densitometry analysis using the VersaDoc™ Imaging system (version 4.0; Bio-Rad Laboratories, Inc.). β-actin was used as the internal control to normalize the samples.

RNA extraction and polymerase chain reaction (PCR). Hippocampi from rats in each group were treated with TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) reagent to extract total RNA following the manufacturer's recommended protocol. Subsequently, genomic DNA was digested using an RNase-free DNase. A total of 4-6 independent RNA samples were used in duplicate in reverse transcription-quantitative (RT-q) PCR analysis. NanoDrop 2000 (Thermo Fisher Scientific, Inc.) was used to detect RNA concentration. Then, cDNA was transcribed from a total of 500 ng DNase I-treated RNA using a cDNA reverse transcription kit (DP304; Tiangen Biotech Co., Ltd., Beijing, China). Primers used in the study were as follows, P2X7R primers: 5'-GGCGGGGTGACGAGTTAGTA-3' (forward) and 5'-TTTTGCTGATCATCCATCTTT-3' (reverse); β-actin primers 5'-TGCTATGTGGCCTCCATGACTTTCG-3' (forward) and 5'-GTTGGCATAGAGGTCTTTACGG-3' (reverse). The temperature protocol was as follows: 37°C 15 min and 95°C 5 min. qPCR analysis was performed on an ABI Prism 7500 sequence detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using Thunderbird SYBR qPCR mix (Toyo Life Science, Osaka, Japan) in 20 µl of reaction mixture. The thermocycling conditions were as follows: Initial denaturation at 95°C for 5 min, followed by 33 cycles of 95°C (15 sec) and 60°C (1 min). Data were analyzed using Sequence Detection Software 1.4 (Applied Biosystems; Thermo Fisher Scientific, Inc.). β-actin was selected as the endogenous reference and data were analyzed using the 2^−ΔΔCq method (15).

Statistical analysis. All values were presented as the mean ± standard deviation of three separate experiments and were analyzed by the one-way analysis of variance, which was used to compare multiple groups, followed by a Bonferroni post-hoc test. An unpaired two-tailed Student's t-test was employed to compare the levels of P2X7 receptor and GFAP and GLU in patients with or without intractable epilepsy. Statistical analysis was performed using SPSS software, version 19.0 (IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Behavioral analysis. Rats injected with pilocarpine hydrochloride exhibited several behavioral events (data not shown), including stereotypical masticatory movements, hypokinesia, head nodding and wet-dog shakes. This behavior rapidly progressed to generalized limbic seizures recurring every 1-3 min and finally culminating in status epilepticus. A total of 4 rats (4.4%) died when injected with the drug and 63 (73%) eventually developed status epilepticus. Behavioral
observations via video surveillance revealed that 28 rats (56%) were in a chronic phase of spontaneous recurrent seizures. Interestingly, one-third reduction in the frequency of spontaneous recurrent seizures was found in the BBG-treated group.

**EEG recordings.** In the control group, EEG recorded waves of 8-10 Hz and 20-120 µV voltages, followed by low β waves and a single δ wave. In sharp contrast, the 28 rats with status epilepticus exhibited great spike-wave discharges (maximum of 28 Hz and 200 µV). Some spike-wave discharges presented individually, whereas others appeared in a short string (Fig. 1).

**P2X7R expression in the rat model**

*Immunohistochemistry.* P2X7R immunoreactivity was found to be high in the cortex, hippocampus, thalamus and amygdala of rats with spontaneous recurrent seizures, but exhibited a significant reduction in the BBG-treated groups 9 [50 mg/kg (V), 100 mg/kg (VI) and 200 mg/kg (VII); Fig. 2], demonstrating a negative correlation with BBG dose. Astroglial activation occurred in the hippocampus of rats with spontaneous recurrent seizures, but this phenomenon was prevented by BBG. Concomitantly, GLU expression was upregulated in rats with spontaneous recurrent seizures compared with the control group, but was also reduced in the BBG-treated groups [50 mg/kg (V), 100 mg/kg (VI) and 200 mg/kg (VII); Fig. 2]. However, there was no significant difference in P2X7R expression between the control group and rats with status epilepticus (I and III, respectively; Fig. 2).

**Western blotting and RT-qPCR.** Western blotting and RT-qPCR analyses demonstrated that P2X7R expression was increased after spontaneous recurrent seizures within the ipsilateral CA3 subfield of the hippocampus. However, there was no difference between the control group and rats with status epilepticus (Fig. 3). In contrast to rats with spontaneous recurrent seizures, P2X7R expression was significantly reduced in the BBG-treated groups (P<0.05).

**P2X7R expression in patients with TLE.** Compared with the control group, immunostaining for P2X7R, GFAP and GLU revealed significant upregulation in the temporal lobe of patients with TLE (P<0.05; Fig. 4).

**Discussion**

To the best of our knowledge, the present study was the first to demonstrate that P2X7R expression is elevated in patients with intractable TLE. This investigation confirmed changes in ATP-gated P2X7R expression in the brain tissue of experimental rats and humans suffering from refractory epilepsy.
Furthermore, the expression of GFAP, an astrocytic protein and Glu, the main excitatory neurotransmitter was measured. The results of the present study demonstrated that the levels of these two proteins were increased in the hippocampus of rats.
In a chronic phase of spontaneous recurrent seizures as well as in the temporal lobe of patients with TLE. Of note, inhibition of P2X7R using BBG, a P2X7R antagonist, effectively reduced the levels of the two proteins in the rat hippocampus. These results suggest that P2X7R may contribute to the pathogenic mechanism of spontaneous seizures and may represent a novel drug target for seizure prevention.

In humans, epilepsy is a neurological emergency associated with various mechanisms, such as proliferation and repeated activation of astrocytes (16), cerebral cortical developmental disorders (17), immunological dysfunction (18) and disturbance of the glutamatergic system (19). A previous study revealed that TLE is a common type of refractory epilepsy that does not appear to respond to initiation of anticonvulsant therapy (20). In the present study, a pilocarpine-induced seizure model was selected, which highly resembles the morphological and synaptic characteristics of TLE in humans. Rats injected with pilocarpine endure a period of status epilepticus followed by a chronic indefinite period of spontaneous recurrent seizures (21).

P2X7R, a purine receptor, is located in multiple parts of the central nervous system, including the hippocampus, cerebellum, thalamus, striatum and nerve terminals, and performs numerous physiological functions, such as adjustment of neurotransmitter release, stimulation of cytokines and chemotactic factors, as well as induction of cell injury and apoptosis. BBG, a new type of biological stain that can cross the blood-brain barrier, has been demonstrated to block P2X7R with no obvious biological toxicity and has been widely applied in recent P2X7R-related studies (22,23). In addition to the discovery of the P2X7R expression trend in the seizure samples, another main finding was that BBG reduced the levels of both GFAP and GLU in the CA3 region of rat hippocampus in a dose-dependent manner. In addition, BBG-treated rats experienced milder seizures compared with rats that were not treated. The expression of P2X7R was also examined in patients with TLE. Immunohistochemical examination demonstrated that P2X7R expression was increased in patients with TLE compared with the control group, which was consistent with the results of the present study's animal research, indicating that P2X7R plays a key role in the pathogenesis of intractable epilepsy. Due to ethical restrictions, normal brain tissue samples could not be obtained; therefore, tissue samples from patients with head trauma were used. In addition, although brain tissue samples were only obtained from patients with refractory epilepsy, the results of the present study may provide some insight into epilepsy in general.

The analysis of GFAP and GLU expression suggested that the possible mechanism through which P2X7R contributes to intractable epilepsy may be associated with preventing enhancement of GLU released by astrocytes. Astrocytes play a central role in maintaining homeostasis of the neuronal microenvironment by means of transporting transmitters (24,25). Studies have found that the process of epilepsy is often accompanied by obvious increases in astrocyte number, as well as changes in morphological and biochemical indicators (26,27). In TLE patients, there was a further decline in the number of principal cells in all hippocampal sub-areas analyzed, which was associated with an increase in GFAP immunoreactivity (28,29). As a vital excitatory neurotransmitter, GLU has been a research focus with regard to central nervous system diseases, such as epilepsy (30). Excessive accumulation of extracellular GLU may lead to excitotoxicity of the neurons through different N-methyl-D-aspartate receptors and eventually trigger a cascade of intracellular signals that result in neuronal death (31). Earlier evidence has revealed that modulation of GLU by astrocytes plays an important role in the homeostasis of extracellular GLU (32,33), thus participating in the molecular pathogenesis of epilepsy (34,35). The present study demonstrated that P2X7R antagonists may be a potential putative therapy independently or in combination with GLU receptor antagonists.

Further research is required to determine whether BBG affects P2X7R and how this signaling mediates astrogliosis. Moreover, further studies are needed to investigate the effects of P2X7R modulation on TLE.

In conclusion, increased levels of P2X7R were observed in patients and experimental animals with intractable TLE. Therefore, P2X7R may be involved in the pathogenesis of TLE and its suppression may provide a new treatment to promote remission in epilepsy.

Acknowledgements

Not applicable.

Funding

The present study was funded by the Natural Science Foundation of Hubei Province in China, (grant no. 02.02.040458).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XD designed the study and drafted the manuscript; PS performed the animal experiments, and was a major contributor in writing the manuscript. JH and XL performed the western blot and PCR assay. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures adhered to the conduct of research involving human subjects established by the National Institutes of Health of China and the Committee on Human Research of Huazhong University of Science and Technology. The present study was approved by the Ethics Committee of Huazhong University of Science and Technology. All subjects provided written informed consent to participate in this study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P and Engel J Jr: Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46: 470-472, 2005.

2. Guangming Z, Wenjing Z, Jiuluan L and Leite JP: Pathophysiology of mood disorders in temporal lobe epilepsy. Rev Bras Psiquiatr 34 (Suppl 2): S233-S243, 2012.

3. Kandratavicius L, Ruggiero RN, Hallak JE, Garcia-cairasco N and Leite JP: Pathophysiology of mood disorders in temporal lobe epilepsy. Rev Bras Psiquiatr 34 (Suppl 2): S233-S243, 2012.

4. Braakman HM, Vaessen MJ, Jansen JP, Debeij-van Hall MH, de Louw A, Hofman PA, Vles JS, Aldenkamp AP and Backes WH: Frontal lobe connectivity and cognitive impairment in pediatric frontal lobe epilepsy. Epilepsia 54: 446-454, 2013.

5. Harden TK, Boyer JL and Nicholas RA: P2-purinergic receptors: Subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 35: 541-579, 1995.

6. Zhang F, Pracheil T, Thornton J and Liu Z: A denosine P2Y receptor antagonist reverses manganese-induced glutamate transporter dynamics in developing astrocytes. J Biol Chem 288: 20992-21000, 2013.

7. Hopfner M, Lemmer K, Jansen A, Hanski C, Riecken EO, Gavish M, Mark B, Buhrt H, Glassmeier G and Scherübel H: Expression of functional P2U-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem Biophys Res Commun 251: 811-817, 1998.

8. Grygorowicz T, Sulejczak D and Struzynska I: Expression of purinergic P2X7 receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits. Acta Neurobiol Exp (Wars) 65: 154-163, 2011.

9. Baines A, Parkinson K, Sim JA, Bragg L, Thompson CR and North RA: Functional properties of five Dictostyelium discoideum P2X2 receptors. J Biol Chem 288: 20992-21000, 2013.

10. Hopfner M, Lemmer K, Jansen A, Hanski C, Riecken EO, Gavish M, Mark B, Buhrt H, Glassmeier G and Scherübel H: Expression of functional P2U-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem Biophys Res Commun 251: 811-817, 1998.

11. Grygorowicz T, Sulejczak D and Struzynska I: Expression of purinergic P2X7 receptor in rat brain during the symptomatic phase of experimental autoimmune encephalomyelitis and after recovery of neurological deficits. Acta Neurobiol Exp (Wars) 65: 154-163, 2011.

12. Norenberg W, Schunk J, Fischer W, Sobotta H, Riedel T, Oliveira JP, Franke H and Illes P: Electrophysiological classification of P2X7 receptors in rat cultured neurocortical astroglia. Br J Pharmacol 160: 1941-1952, 2010.

13. Eleftheriadis T, Pissas G, Karioti A, Antoniadis G, Gollinopoulos S, Liakopoulos V, Mamara A, Speletas M, Kouklis G and Stelidis P: Nicotinic acid induces caspase-1 activation, IL-1β secretion and P2X7 receptor-dependent proliferation in primary human lymphocytes. Hippokratia 17: 141-145, 2013.

14. Skaper SD, Debetto P and Giusti P: The P2X7 purinergic receptor: From physiology to neurological disorders. FASEB J 24: 337-345, 2010.

15. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25: 402-408, 2001.

16. Heja L: Astrocytic target mechanisms in epilepsy. Curr Med Chem 21: 755-763, 2014.

17. Chaukheidze G, Koppelstaetter F, Unterberger I, Dobesberger J, Walser G, Höfler J, Zamanian L, Haberlandt E, Rostasy K, Oestreicher A, Jansen GH, Riedel T, Veelen CW, Wang RK and Boison D: Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice. J Neurosci 120: 628-638, 2014.

18. Lee ES, Sidoryk M, Jiang H, Yin Z and Aschner M: Estrogen increases calcium accumulation in astrocytes: Evidence following inhibition with tamoxifen. Exp Eye Res 177: 145-149, 2018.

19. Peng WF, Ding J, Mao LY, Li X, Liang L, Chen CZ, Cheng WZ, Fan W and Wang X: Increased ratio of glutamate-glutamine to creatine in the right hippocampus contributes to depressive symptoms in patients with epilepsy. Epilepsy Behav 29: 144-149, 2013.

20. Menon R, Radhakrishnan K and Radhakrishnan K: Status epilepticus. J Assoc Physicians India 61 (8 Suppl): S58-S63, 2013.

21. Grabenstatter HL, Del AL, Carlsen J, Wempe MF, White AM, Cogswell M, Russek SJ and Brooks-Kayal AR: The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy. Neurobiol Dis 62: 73-85, 2014.

22. Sakamoto K, Inukai M, Mori A and Nakahara T: Brilliant Blue G protects against photoreceptor injury in a murine endotoxin-induced uveitis model. Exp Eye Res 177: 145-49, 2018.

23. Bartlett R, Sutry V, Watson D, Sutry K and Verbury JJ: P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1(G93A) amyotrophic lateral sclerosis mice. Peeln S: c5064, 2017.

24. Hussmann KL, Samuel MA, Kim KS, Diamond MS and Frederiksen BL: Differential replication of pathogenic and nonpathogenic strains of West Nile virus within astrocytes. J Virol 87: 2814-2822, 2013.

25. Benediktsson AM, Mars G, Tu JC, Wroley PF, Rothstein JD, Bergles DE and Dailey ME: Neuronal activity regulates glutamate transporter dynamics in developing astrocytes. Glia 60: 175-188, 2012.

26. Kozela E, Juknat A and Vogel Z: Modulation of astrocyte activity by cannabidiol, a nonpsychoactive cannabinoid. Int J Mol Sci 18: pii: E1669 2017.

27. Shen HY, Sun H, Hanthorn MM, Zhi Z, Lan QJ, Poul sen DJ, Wang RK and Boison D: Overexpression of adenosine kinase in cortical astrocytes and focal neocortical epilepsy in mice. J Neurosci 120: 628-638, 2014.

28. Peixoto-Santos JE, Velasco TR, Galvis-Alonso OY, Araujo D, Kandratavicius L, Assirati JA, Carlotti CG, Scanducci RC, Santos AC and Leite JP: Temporal lobe epilepsy patients with severe hippocampal neuron loss but normal hippocampal volume: Extracellular matrix molecules are important for the maintenance of hippocampal volume. Epilepsia 56: 1562-1570, 2015.

29. Proper EA, Oestreicher AB, Jansen GH, Veelen CW, van Rijen PC, Gispen WH and de Graan PN: Immunohistochemical characterization of mossy fibre sprouting in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 123 (Pt 1): 19-30, 2010.

30. Swamy AH, Patel NL, Gadad PC, Koti BC, Patel UM, Thippeswamy AH and Manjula DV: Neuroprotective activity of pongamia pinnata in monosodium glutamate-induced neurotoxicity in rats. Indian J Pharm Sci 75: 657-663, 2013.

31. Zhi S and Paoletti P: Allosteric modulators of NMDA receptors: Multiple sites and mechanisms. Curr Opin Pharmacol 20: 14-23, 2015.

32. Jiang S, Wang YQ, Xu CF, Li YN, Guo R and Li L: Involvement of connexin43 in the infrasonic noise-induced glutamate release by cultured astrocytes. Neurochem Res 39: 833-842, 2014.

33. Morales I and Rodriguez M: Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia 60: 1481-1494, 2012.

34. Sheean RK, Lau CL, Shin YS, O'Shea RD and Beart PM: Links between L-glutamate transporters, NA+/K+-ATPase and cytokine skeleton in astrocytes: Evidence following inhibition with rotterlin. Neuroscience 254: 335-346, 2013.

35. Lee ES, Sidoryk M, Jiang H, Yin Z and Aschner M: Estrogen and tamoxifen reverse manganese-induced glutamate transporter impairment in astrocytes. J Neurochem 110: 530-544, 2009.